# NHS National Generic Pharmaceuticals Wave 13

> Tender notice from UK public-sector procurement sources.

## Key facts

- Public buyer: [NHS England](/buyers/nhs-england/contract-awards)
- Tender value: £710,767,138
- Published: 21 June 2021
- Planned start: 1 February 2022
- Planned end: 31 May 2024
- Stage: open_tender
- Procurement category: goods
- Notice ID: 3a757f1b-d279-4a70-b99c-b077c5caa22b-445208
- OCID: ocds-b5fd17-582c14ad-7a7d-400d-864c-5d539c4b1eae

## Description

Tender Close: 26th July 2021, 13:00\. Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend \(at the Authority's sole discretion\) for a period or periods up to a total of 48 months\. Potential periods of call-offs under the framework agreement: Transition \(Everolimus\) CESW: 1 March 2022 - 30 September 2023 \(19 months\) LSNE: 1 March 2022 - 31 January 2023 \(11 months\) NWLN: 1 March 2022 - 31 January 2023 \(11 months\) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 \(27 months\) Hospital Only Products CESW: 1 February 2022 - 30 September 2023 \(20 months\) LSNE: 1 February 2022 - 31 May 2024 \(28 months\) NWLN: 1 February 2022 - 31 January 2023 \(12 months\)

## Related contract awards

- [Transformation Delivery Services - Establishing Operational Excellence \(EOE\)](/contracts/ocds-b5fd17-b08595d2-8961-409b-9b62-7b01d7a64541): NHS England
- [Identity Access Management - Service Adoption and Enablement](/contracts/ocds-b5fd17-08ebad6c-84fb-4e62-9afd-d06d220dd3a5): NHS England
- [OutSystems licenses for MAPPTI \(AP&P\)](/contracts/ocds-b5fd17-521fbf90-6e93-4366-b3bc-47aa2efd447d): NHS England

## Source

[View the original notice on Contracts Finder](https://www.contractsfinder.service.gov.uk/Notice/3a757f1b-d279-4a70-b99c-b077c5caa22b-445208)